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Background: Thiopurine S-methyltransferase (TPMT) is an 
important enzyme in the metabolism of thiopurines includ-
ing azathioprine (AZA), 6-mercaptopurine, and 6-thiogua-
nine. TPMT genotyping is widely used for screening of 
AZA-related toxicity during routine clinical practice in 
Korea. However, the data of TPMT genotypes and its AZA-re-
lated toxicity have not been studied in the field of 
dermatology. Objective: The aim of this study was to eval-
uate the genetic basis of TPMT polymorphism in Korean der-
matologic patients and subsequently to investigate the rela-
tionship between mutant TPMT and adverse responses to 
AZA treatment. Methods: This study was retrospective, sin-
gle-center study. One hundred forty-nine Korean dermato-
logic patients who underwent TPMT screening test were 
included. Each patient’s medical records, the result of TPMT 
screening test, dose and treatment period of AZA, and side ef-
fects, were reviewed. Laboratory tests were assessed at each 
visit in order to monitor adverse drug reactions. Leukopenia 
grading was used in accordance with the common terminol-
ogy criteria for adverse events (CTCAE) ver. 4.03. Results: 
Behçet’s disease was the leading disorder among the 
patients. The frequency of TPMT mutation was 4.0% (6/149) 
among the participants in this study. Four of the six patients 
with genetic alterations were treated with a low-dose AZA 
regimen, but no AZA-related adverse events were observed. 
Conclusion: Our results suggest that 1) TPMT polymor-
phisms in Korean dermatologic patients are similar to those 
previously reported in Asian patients with the most common 
mutant allele being TPMT*3C and 2) AZA can be used in the 
patients with these polymorphisms under a careful dosing 
regimen. (Ann Dermatol 29(5) 529∼535, 2017)
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INTRODUCTION
Thiopurine agents, such as 6-mercaptopurine, 6-thio-
guanine, and azathioprine (AZA), are widely used for the 
treatment of acute leukemias, inflammatory bowel dis-
eases, and other immunological disorders1,2. AZA has 
been reported to be effective in treating various dermato-
logic diseases and is frequently used in an off-label man-
ner for different inflammatory skin diseases, including 
Behçet’s disease (BD), atopic dermatitis, psoriasis, and 
photodermatoses3. However, when treating patients with 
AZA, dermatologists should be aware of possible side ef-
fects, such as myelotoxicity, which could result in severe 
immunosuppression and even death, requiring dis-
continuation of the treatment4. In this context, catego-
rization of high-risk patients before treatment may be help-
ful to physicians in differing clinical settings.
Clinically, thiopurine S-methyltransferase (TPMT) genotyp-
ing is used to screen for AZA-related toxicity; genetic poly-
morphisms in the TPMT gene can affect protein stability 
and may lead to decreased TPMT activity5. Patients with 
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high TPMT activity are resistant to AZA due to the catabo-
lizing effect of TPMT converting thiopurine drugs into 
6-methylmercaptopurines (6-MMPs)6. On the other hand, 
patients with low TPMT activity have elevated 6-thio-
guanine nucleotide (6-TGN) levels and may be at in-
creased risk of bone marrow (BM) suppression5. In Korea, 
TPMT genotyping is generally available and has been 
widely used for the screening of AZA-related toxicity dur-
ing routine clinical practice. However, the data of TPMT 
genotypes and its AZA-related toxicity have not been stud-
ied in the field of dermatology.
The aims of this study were to evaluate the genetic basis 
of TPMT polymorphism in patients with dermatological 
diseases and subsequently to investigate the relationship 
between mutant TPMT and adverse responses observed in 
Korean patients treated with AZA for various dermatologic 
conditions.
MATERIALS AND METHODS
Patients
Retrospective Clinical Data Retrieving System data 
(Severance Hospital, Seoul, Korea) were used to obtain 
clinical and laboratory information from patients who vis-
ited our dermatology clinic and underwent a TPMT 
screening test between June 2013 and July 2014. A total 
of 149 Korean patients with various dermatoses were 
identified, and 123 of them received treatment with AZA. 
In these 123 patients, a review of each patient’s medical 
records, including age, sex, comorbidities, medications, 
the result of the TPMT screening test, dose and treatment 
period of AZA, and side effects, was performed. This retro-
spective study was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea (IRB no. 4-2015-025).
Analysis of the TPMT genotype
Whole blood specimens were collected into EDTA tubes, 
and genomic DNA was isolated from peripheral blood 
leukocytes using the QIAsymphony DSP DNA Mini kit 
(QIAGEN GmbH, Hilden, Germany) and QIAsymphony 
SP (QIAGEN GmbH, Hombrechtikon, Switzerland) ac-
cording to the manufacturer’s instructions.
Three exons, TPMT*3B exon 6 (460G＞A Ala154Thr), 
TPMT*3C exon 9 (719A＞G Tyr240Cys) and TPMT*6 
exon 7 (539A＞T Tyr180Phe), of the TPMT gene were am-
plified on a model C1000/S1000TM thermal cycler 
(BIO-RAD, Singapore) using biotin attached modified oli-
gonucleotide primers. Pyrosequencing was performed 
with PyroMark Q24 MDx (QIAGEN GmbH, Sollentuna, 
Sweden) using PyroMark Gold Q24 kit (QIAGEN GmbH, 
Hilden, Germany) according to the manufacturer’s 
instructions. To identify sequence variations, patients’ se-
quences were compared with respective reference se-
quences using the PyroMark software ver. 2.0 (QIAGEN 
GmbH, Hilden, Germany).
Laboratory monitoring and adverse events
Laboratory tests were reviewed at each visit in order to 
monitor adverse drug reactions. Routine blood examina-
tions, including a complete blood cell count, erythrocyte 
sedimentation rate, albumin, transaminase, amylase, li-
pase, and C-reactive protein, were carried out. Any re-
cords of adverse events and symptoms that patients com-
plained about were reviewed within the follow-up period. 
The time interval in which the adverse events developed 
after the administration of AZA was also investigated. In 
addition, medications which are known to cause drug in-
teraction when used concomitantly with AZA were 
analyzed.
BM suppression
Leukopenia was defined as a white blood cell (WBC) 
count ＜4,000/mm3, categorized as follows: grade 1, 
WBC count ≥3,000/mm3 and ＜4,000/mm3; grade 2, 
WBC count ≥2,000/mm3 and ＜3,000/mm3; grade 3, 
WBC count ≥1,000/mm3 and ＜2,000/mm3; grade 4, 
WBC count ＜1,000/mm3. This classification was used in 
accordance with the common terminology criteria for ad-
verse events (CTCAE) ver. 4.03.
Statistical analysis
Discrete variables were described using frequency 
(percentages), and continuous variables were reported us-
ing median (range) or mean (standard deviation). The 
chi-square test was performed to evaluate the occurrence 
of AZA-induced BM suppression in patients subgroups 
categorized according to the use of aminosalicylates, and 
one-way ANOVA test was performed to analyze relation-
ship between onset and severity of leukopenia. IBM SPSS 
Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) was used, 
with p＜0.05 considered statistically significant.
RESULTS
Clinical characteristics of the patients
A total of 149 patients were studied. The average patient 
age was 48.6±13.2 years, and the male to female ratio 
was 1:1.98. There were 116 (77.3%) cases of BD, which 
was the most common disease among patients evaluated 
for TPMT mutations, followed by atopic dermatitis (6.7%), 
lichen planus (2.7%), and chronic eczema (2.7%). In the 
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Table 1. Baseline characteristics of analyzed patients
Factors TPMT wild type (n=143) TPMT heterozygotes (n=6) Total (n=149)
Demographics
Age (yr) 48.6±13.1 48.5±19.5 48.6±13.2
Sex
Male 47 (32.9) 3 (50.0) 50 (33.6)
Female 96 (67.1) 3 (50.0) 99 (66.4)
Disease
Behçet disease 111 5 116 (77.3)
Atopic dermatitis 10 0 10 (6.7)
Lichen planus 4 0 4 (2.7)
Chronic eczema 3 1 4 (2.7)
Allergic contact dermatitis 3 0 3 (2.0)
Dermatomyositis 2 0 2 (1.3)
Psoriasis vulgaris 2 0 2 (1.3)
Chronic urticaria 2 0 2 (1.3)
Others* 6 0 6 (4.0)
Administration of AZA
Number of patients 119 (83.2) 4 (66.7) 123 (82.6)
Dosage (mg/d) 62.02±22.68 43.75±12.50 61.42±22.72
Duration (d) 1,211.05±929.66 1,074.25±654.23 1,206.61±924.20
Values are presented as mean±standard deviation, number (%), or number only. TPMT: thiopurine S-methyltransferase, AZA: 
azathioprine. *These include alopecia areata, erythema multiforme, seborrheic dermatitis, vitiligo, onychomycosis, and skin graft versus 
skin disease.
Table 2. ADRs during azathioprine treatment
ADR
Wild type 
(n=119)
TPMT heterozygotes 
(n=4)
Leukopenia 40 (81.5) 0
Grade 1 30 0
Grade 2 8 0
Grade 3 0 0
Grade 4 2 0
Hepatitis 2 (4.3) 0
Fatigue 3 (6.4) 0
Cold 1 (2.1) 0
Eczema herpeticum 1 (2.1) 0
Total 47 0
Values are presented as number (%) or number only. ADR: 
adverse drug reaction, TPMT: thiopurine S-methyltransferase.
analysis of TPMT genotyping, 143 cases (96.0%) were 
wild type (*1/*1), and 6 patients (4.0%) had at least one 
mutated TPMT allele. A total of 123 patients were treated 
with AZA, including four patients with a TPMT mutation. 
The mean dose of AZA was 61.42±22.72 mg/d, 
62.02±22.68 mg/d, 43.75±12.50 mg/d in the total pop-
ulation, wild-type patients, and TPMT-mutated patients, 
respectively. The mean total duration of AZA treatment 
was 1,206.61 days, 1,074.25 days, and 1,211.05 days in 
the total population, wild-type patients, and TPMT-mu-
tated patients (Table 1). Comorbidities in AZA-treated pa-
tients were evaluated, in which gastrointestinal BD was 
the most common, followed by hypertension (Supplemen-
tary Table 1).
Adverse drug reaction during AZA treatment
Among the 123 patients treated with AZA, an adverse 
drug reaction occurred in 47 patients (38.2%). Among 
these patients, hepatitis occurred in 2 (4.3%) patients, fa-
tigue in 3 (6.4%), the common cold in 1 (2.1%), and ecze-
ma herpeticum in 1 (2.1%) patient. Leukopenia comprised 
81.5% (n=40) of all adverse reactions, with most patients 
experiencing a mild degree of leukopenia. Patients dis-
played grade 1 leukopenia (30), grade 2 leukopenia (8), or 
grade 4 leukopenia (2); none displayed grade 3 leuko-
penia. There were no adverse events reported among 
those treated with AZA, even in the four patients with a 
TPMT mutation (Table 2). Among the medications that are 
known to cause drug interaction with AZA, only amino-
salicylate was taken concurrently with AZA in some of the 
patients. The analysis evaluating the effect of concomitant 
usage of aminosalicylates on the occurrence of AZA-in-
duced BM suppression did not show statistical sig-
nificance (Supplementary Table 2). 
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Fig. 2. Changes in leukocyte counts over the follow-up interval 
in azathioprine (AZA)-treated patients heterozygous for a 
thiopurine S-methyltransferase (TPMT) mutation (n=4). The red 
dashed line indicates the threshold minimal value for grade 1 
leukopenia according to the common terminology criteria for 
adverse events (CTCAE) ver. 4.03. The follow-up period ranged 
from 1 to 6 years. None of the AZA-treated patients developed 
leukopenia during the follow-up period. WBC: white blood cell.
Table 3. Characteristics of patients with TPMT mutations (n=6)
Patient 
no.
Age (yr)/
sex
Disease
TPMT 
mutation
Nucleotide 
variation
Use of 
AZA
Daily 
dosage (mg)
Total 
duration (d)
Total 
dosage (mg)
ADR
1 49/M Behçet’s disease *1/*3C c.719A＞G – -
2 53/M Behçet’s disease *1/*3C c.719A＞G + 50 1,310 65,500 None
3 76/F Behçet’s disease *1/*3C c.719A＞G + 50 850 42,500 None
4 49/F Behçet’s disease *1/*3C c.719A＞G + 50 1,836 91,800 None
5 15/F Chronic eczema *1/*3C c.719A＞G + 25 361 9,025 None
6 49/M Behçet’s disease *1/*6 c.539A＞T – -
TPMT: thiopurine S-methyltransferase, AZA: azathioprine, ADR: adverse drug reaction, M: male, F: female.
Fig. 1. The time interval of bone marrow suppression after 
azathioprine (AZA) treatment. Total 40 patients with leukopenia 
were analyzed; grade 1 leukopenia (30), grade 2 leukopenia (8), 
and grade 4 leukopenia (2). Onset of leukopenia relates to time 
from the start of AZA treatment to the detection of leukopenia 
(medians are indicated).
The time interval of BM suppression after AZA treatment
In 40 patients who experienced leukopenia, the mean 
time interval of occurrence of leukopenia was 1,044.75± 
941.55 days, and its range varied from 20 to 3,635 days. 
However, two patients who developed severe leukopenia 
(grade 4) showed short time interval of occurrence (20 
and 40 days), and the onset of BM suppression had a ten-
dency to be shorter with increased grade of leukopenia 
despite of statistically insignificance (p=0.11). In each 
group, the mean time interval was 1,208 days, 686.25 
days, and 30 days in the grade 1 leukopenia, grade 2 leu-
kopenia, and grade 4 leukopenia, respectively (Fig. 1).
Patient characteristics of those with a TPMT mutation
The TPMT genotype of most patients was *1/*1 (wild 
type). Six patients had a mutant TPMT genotype, and the 
distribution was as follows. Four patients with BD and one 
patient with chronic eczema had *1/*3C (heterozygous), 
and one patient with BD had *1/*6 (heterozygous). Of 
note, the four patients heterozygous for a TPMT mutation 
were treated with AZA with an initial and maintenance 
dosage in the 25 to 50 mg per day range, and the total 
treatment duration ranged from 361 to 1,836 days. 
Regardless of the presence of a TPMT mutation, none of 
patients treated with AZA experienced additional incon-
venience, and their laboratory assessments all remained 
stable, without any definite adverse events, including leu-
kopenia (Table 3).
WBC changes in TPMT heterozygotes during AZA 
treatment
Laboratory findings were reviewed during AZA treatment 
in the four patients heterozygous for a TPMT mutation. 
Treatment periods varied from 1 to 6 years. During fol-
low-up, WBC counts were consistently above 4,000/mm3 
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in all four patients, which represents the criteria for a 
grade 1 leukopenia (Fig. 2). In addition, no cases of BM 
toxicity defined as neutropenia, thrombocytopenia, or 
anemia were reported during the treatment period (data 
are not shown).
DISCUSSION
AZA has been commonly used for more than 30 years to 
manage various dermatoses, and the drug is still sub-
stantially affordable. Dermatologists commonly prescribe 
AZA for atopic dermatitis, psoriasis, photodermatosis, im-
munobullous disease, and various other dermatologic 
conditions3. One of the severe side effects of AZA treat-
ment that must be managed is myelosuppression, which 
should be closely monitored. AZA is a type of pro-drug 
that is activated after serial metabolism by multiple 
enzymes. Among those enzymes, alterations in TPMT are 
known to be correlated with AZA toxicity6.
Recently, other pharmacogenetic markers, such as inosine 
triphosphate pyrophosphatase and nucleoside diphos-
phate linked moiety X-type motif 15, have been suggested 
for screening of AZA-related toxicity7,8. However, clinical 
application of screening tests for these markers is still a 
long way from actually being marketed. Accordingly, 
TPMT genotyping is commonly used for screening of 
AZA-related toxicity during routine clinical practice in 
Korea.
TPMT is an important enzyme that metabolizes thiopurines. 
When AZA is absorbed by cells, the pro-drug is rapidly 
converted to its active metabolites, such as 6-mercapto-
purine, 6-thioinosine monophosphate, and 6-TGN. TPMT 
catabolizes these active metabolites into inactive forms 
like 6-MMP9. Reduced enzymatic activity of TMPT is asso-
ciated with increased 6-TGN levels, which may result in 
direct incorporation of 6-TGN into DNA and cause cyto-
toxicity and immunosuppression by inhibition of RNA, 
DNA, and protein synthesis9,10.
Although allelic variations in TPMT affect protein stability 
or enzyme activity, there are ＞30 TPMT alleles. The 
wild-type allele is TPMT*1, and the majority of alleles re-
lated to low enzyme activity of TPMT are represented by 
*2, *3A, *3B and *3C; TPMT*2 results in 26%, TPMT*3A 
results in 1.6%, TPMT*3B results in 1.7% and TPMT*3C 
results in 17% of enzymatic activity compared with wild 
type in vitro11,12. In Caucasians, TPMT*3A is the most 
common mutant allele; however, in East Asia the TPMT*3C 
is most frequently reported gene polymorphism13,14.
In our study, similar to previous data reported involving 
Asian patients, the most common mutant allele was 
TPMT*3C. Additionally, the frequency of the TPMT*3C 
allele in our study was 3.4% (5/149), consistent with the 
reported Korean data in other inflammatory diseases 
(frequency of 2.4%∼4.4%)15-18. We also detected one 
TPMT*6 allele in a patient with BD. This rare TPMT*6 
mutant allele has been previously reported in one 
Malaysian blood sample in 200219. Several additional 
TPMT*6 mutations have been reported only in Korean pa-
tients; whereas, no TPMT*6 alleles have been found even 
in Japanese or Chinese patients, who were thought to 
have similar genotypic features with Koreans15,20,21. The 
clinical relevance of the TPMT*6 allele has not yet been 
clarified, but this variant might be a candidate for a TPMT 
pharmacogenetics study, especially in Korea.
We evaluated for a possible relationship between TPMT 
gene mutations and adverse response to AZA. Because 
there were no reported AZA-related adverse events in our 
patients with TPMT mutations, we could not investigate 
the relationship between the TPMT genotype and adverse 
events, including leukopenia. In a similar study of the pa-
tients with systemic lupus erythematosus analyzed the re-
lationship between TPMT mutations and their adverse ef-
fects, mean dosage of AZA in TPMT mutated patient was 
low (60.71±22.72 mg/d) and there was no statistically sig-
nificant correlation between TPMT genotype and AZA tox-
icity15. 
In this study, adverse events were found only in patients 
with wild-type TPMT. The majority of reported events 
were grade 1 leukopenias, and most adverse events were 
not severe with only two cases of mild hepatitis, which 
did not require discontinuation of AZA. However, in two 
of forty patients with leukopenia, severe leukopenia (grade 
4) occurred abruptly. Though, there was no significant dif-
ference found between the grade and onset of leukopenia, 
the onset had a tendency to be shorter with increased 
grade of leukopenia. Since the onset of myelosuppression 
is unpredictable and severe leukopenia occurred in a short 
onset time of 6 weeks in this study, blood count should be 
monitored frequently in the early period of AZA use. 
In addition, concomitant medications including allopur-
inol, aminosalicylate (sulfasalazine and mesalazine), co- 
trimoxazole, angiotensin converting enzyme inhibitors, 
and ribavirin, which are known to cause drug interaction 
with AZA, may increase the risk of AZA-related BM 
toxicity. In a previous study, concurrent administration of 
AZA with aminosalicylate for treatment of inflammatory 
bowel disease led to a significant increase in the fre-
quency of leukopenia22. In this study, there were patients 
taking aminosalicylate, thus we also evaluated the associa-
tion of the medication and AZA-related toxicity. However, 
the effect of concomitant usage of aminosalicylates on the 
occurrence of AZA-induced BM suppression did not show 
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any statistical significance (Supplementary Table 2). 
The AZA dosage for patients with TPMT mutations was ≤50 
mg/d. This range of AZA dosage is generally used to treat 
dermatologic disease but might be too low to cause a 
myelosuppressive effect. Several studies have reported 
that some individuals with a heterozygous genotype ex-
hibit high enzyme activity; whereas, some homozygous 
wild type subjects exhibit an intermediate phenotype6. A 
possible hypothesis that can explain these phenomena is 
that the single nucleotide polymorphisms discussed so far 
are not the only factors regulating the TPMT’s catalytic ac-
tivity, and the genotype at the major locus, which regu-
lates TPMT activity, accounts for only approximately 
two-thirds of the total variance in population genetic stud-
ies10. Various other factors, like promoter polymorphisms, 
drug interactions, diagnosis, and environmental factors, 
could be related. Although TPMT genotyping could not 
completely explain the high frequency of BM suppression 
during AZA treatment, obtaining TPMT genotypes in all 
patients before starting AZA treatment could still be rea-
sonable, due to the mechanism-based theory and pre-
viously reported results of increased myelosuppression 
risk in patients with low or absent TPMT enzyme activity. 
It is reported that all patients with inactive homozygous 
TPMT genotype who were treated with conventional 
doses of AZA (1.5 mg/kg/d) experience severe myelosup-
pression and 30%∼60% of patients with heterozygous 
TPMT genotype developed severe myelosuppression with 
standard doses of AZA23. In similar studies with conven-
tional dose of AZA in rheumatologic diseases and in-
flammatory bowel diseases, there was increased risk of 
myelosuppression in heterozygous TPMT group24-26. 
Notably, such patients typically receive a higher AZA dos-
age than dermatological patients (1.5∼2.5 mg/kg/d, gen-
erally over ＞100 mg/d). Since there were no adverse 
events in any of the four TPMT heterozygous patients 
treated with AZA in our study, we carefully recommend 
that the low-dose AZA generally used to treat dermato-
logic conditions can be cautiously used under close mon-
itoring even in patients with heterozygous minor alleles.
However, this study has some limitations. This was a ret-
rospective study conducted in a single center, and only a 
small number of patients possessing a mutant TPMT geno-
type were assessed. Furthermore, we could not evaluate 
for additional metabolites that are related to examining 
TPMT enzymatic activity. Also, because this is a retro-
spective study, there may be selection bias, in which a 
lower dosage of AZA was used in the TPMT mutation 
group than the wild type group, therefore, this report does 
not imply that conventional dosage of AZA in patients 
with TPMT mutations is as safe as those in naïve patients. 
In addition, the majority of the patient population consists 
of BD, which may have possible influences on the results. 
Thus the differences between patients with and without 
BD should be also studied in the further evaluation. 
Accordingly, prospective, randomized, controlled trials 
are needed to determine a more definite correlation be-
tween the TPMT genotype and risk of adverse events asso-
ciated with usage of AZA in patients with dermatologic 
disorders.
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Supplementary Table 1. Comorbidities in azathioprine treated patients (n=83)
With BM suppression Without BM suppression Total
Gastrointestinal Behçet's disease 6 11 17 (20.5)
Neuro-Behçet's disease 1 5 6 (7.2)
Hypertension 6 5 11 (13.3)
Diabetes mellitus 2 2 4 (4.8)
Chronic renal failure 0 1 1 (1.2)
Old pulmonary tuberculosis 1 0 1 (1.2)
Crohn's disease 1 2 3 (3.6)
Ulcerative colitis 1 1 2 (2.4)
Chronic hepatitis 2 0 2 (2.4)
Old pulmonary tuberculosis 1 0 1 (1.2)
Asthma 1 1 2 (2.4)
Sjogren's syndrome 1 0 1 (1.2)
Myasthenia gravis 0 1 1 (1.2)
Osteopenia and Osteoporosis 2 8 10 (12.0)
Spinal stenosis 1 2 3 (3.6)
Atrial fibrillation 1 0 1 (1.2)
Deep vein thrombosis 1 4 5 (6.0)
Arteriovenous malformation 0 1 1 (1.2)
Artherosclerosis 0 1 1 (1.2)
Benign prostatic hyperplasia 0 2 2 (2.4)
Thyroid cancer 2 1 3 (3.6)
Ovarian cancer 0 1 1 (1.2)
Depression 0 2 2 (2.4)
Migrane 0 2 2 (2.4)
Values are presented as number only or number (%). BM: bone marrow.
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Supplementary Table 2. Relationship between aminosalicylate usage and AZA-induced BM suppression
Usage of aminosalicylate
BM suppression
Total p-value
Present Absent
Aminosalicylate(+) 6 (37.5) 10 (62.5) 16  0.648*
Aminosalicylate(–) 34 (31.8) 73 (68.2) 107
Values are presented as number (%) or number only. AZA: azathioprine, BM: bone marrow. *χ2=0.208.
